EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study
Abstract
Authors
M Filippi L Grimaldi A Conte R Totaro MR Valente S Malucchi F Granella C Cordioli V Brescia Morra D Perini L Santoni